Valuation: Adimmune Corporation

Market Cap 7.46B 234M 200M 188M 172M 324M 22.3B 327M 2.21B 862M 11.25B 878M 859M 37.25B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 8.07B 253M 217M 203M 186M 350M 24.12B 354M 2.4B 933M 12.17B 950M 929M 40.31B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 day-0.56%
1 week+2.31%
Current month+6.95%
1 month+3.81%
3 months+1.72%
6 months-1.39%
Current year-6.60%
1 week 17.6
Extreme 17.6
18.55
1 month 16.4
Extreme 16.4
18.55
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 2019-06-19
Director of Finance/CFO - 2020-12-31
Chief Tech/Sci/R&D Officer - 2022-01-25
Director TitleAgeSince
Director/Board Member 72 2019-06-19
Director/Board Member - 2011-08-14
Chairman - 2008-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%+2.31%-0.84%-46.36% 234M
+0.61%+2.88%+45.63%+0.39% 83.24B
-0.69%+3.58%-19.85%-35.64% 59.49B
+14.36%+152.27%+526.55%+41.90% 63.41B
+0.76%+3.53%+0.08%+36.18% 52.94B
-1.74%+1.10%+10.24%+167.95% 49.86B
+1.21%+3.87%+61.90%-16.51% 32.62B
+1.36%+5.06%+53.04%+103.13% 26.29B
+9.69%+11.76%+14.67%+215.97% 22.23B
-0.79%0.00%+60.77%+122.35% 17.22B
Average +0.73%+18.72%+75.22%+58.93% 40.75B
Weighted average by Cap. +0.19%+27.35%+101.36%+48.90%

Financials

2024 2025
Net sales 1.56B 48.81M 41.82M 39.19M 35.8M 67.55M 4.65B 68.22M 462M 180M 2.35B 183M 179M 7.77B 1.4B 43.93M 37.64M 35.27M 32.22M 60.81M 4.19B 61.41M 416M 162M 2.11B 165M 161M 7B
Net income -243M -7.61M -6.52M -6.11M -5.58M -10.53M -725M -10.64M -72.07M -28.06M -366M -28.57M -27.95M -1.21B -240M -7.52M -6.44M -6.04M -5.52M -10.41M -717M -10.51M -71.22M -27.72M -362M -28.23M -27.62M -1.2B
Net Debt 140M 4.37M 3.75M 3.51M 3.21M 6.05M 417M 6.11M 41.43M 16.13M 210M 16.43M 16.07M 697M 612M 19.19M 16.45M 15.41M 14.08M 26.57M 1.83B 26.83M 182M 70.76M 923M 72.06M 70.49M 3.06B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
26-08-25 NT$17.70 -0.56% 498,993
26-08-24 NT$17.80 -1.93% 1,636,513
26-08-21 NT$18.15 +0.28% 2,013,422
26-08-20 NT$18.10 +4.93% 4,567,532
26-08-19 NT$17.25 -0.29% 451,127
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock